"Breakthrough: MDXX Drugs Unveiled as Promising Treatment for Autism and Schizophrenia in Teens"

Researchers at the University of Rochester have identified a potential treatment target for neuropsychiatric disorders like autism and schizophrenia during critical periods of brain development. By stimulating underperforming neurons in the dopamine system that connect to the frontal cortex, they were able to rescue structural brain deficiencies and potentially alter the course of the diseases, with long-lasting effects into adulthood. This discovery could lead to targeted interventions during key developmental windows, offering the possibility of changing the trajectory of these disorders.